Nucala® (mepolizumab) is now listed on the PBS

Nucala® (mepolizumab) is now listed on the pharmaceutical benefits scheme (PBS) for Australians with chronic rhinosinusitis with nasal polyps.

As the first biologic treatment to be PBS-subsidised for the treatment of severe chronic rhinosinusitis with nasal polyps, the availability of Nucala on the PBS provides Australians living with this chronic condition affordable access to a treatment that may help to effectively improve their health and wellbeing and reduce the burden of disease.

Speak to your GP to discuss the appropriate management of your condition and for referral to a specialist when needed.

For more info click here.